What's Going On With bioAffinity Technologies Stock Wednesday? - bioAffinity Technologies (NASDAQ:BIAF) bioAffinity Technologies Inc (NASDAQ: BIAF) shares trade higher in Wednesday's premarket after announcing a live virtual roundtable for its CyPath Lung test.

What's Going On With bioAffinity Technologies Stock Wednesday? bioAffinity Technologies Inc (NASDAQ: BIAF) shares trade higher in Wednesday's premarket after announcing a live virtual round...

#benzai #BIAF #Equities #News #why #it's #moving #Top #Stories #Markets #Movers

Origin | Interest | Match

New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures bioAffinity Technologies (Nasdaq: BIAF) published a clinical case study showing its noninvasive CyPath® Lung test informed care for a 71-year-old high-risk patient with multiple pulmonary nodules.The test returned an “Unlikely Malignancy” result; a three-month CT follow-up in October 2025 showed resolution of suspicious nodules and stability of another, avoiding invasive biopsy.Clinical study metrics: 92% sensitivity, 87% specificity, 88% accuracy for detecting lung cancer in nodules 20 mm.

#BIAF #BIAFW New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

www.stocktitan.net/news/BIAF/new-case-study...

$BIAF on a roll, ripping over 120%! Early morning premarket movers like this one getting attention.

Today’s most trending tickers with positive sentiment (last 24h):

$SPY: 33
$ADBE: 15
$NVDA: 12
$POET: 11
$USO: 10
$MU: 9
$IPM: 9
$GME: 8
$BTC: 8
$TSLA: 7
$SPX: 7
$META: 6
$BIAF: 6
$LITM: 6
$TVGN: 5
$EONR: 5
$USD: 4
$MSTR: 4

Original post on benzinga.com

Crude Oil Gains Over 1%; VEON Shares Spike Higher US stocks mostly lower, Nasdaq drops 0.71%, Dow up 0.03%. Utilities up 1.2%, communication services down 1.2%. PCE index rose 2.8%, GDP up 0.7%. Im...

#BIAF #Equities #IBG #IMMP #KLC #LOCO #Mid-Day #Market […]

[Original post on benzinga.com]

OdaSkillsInvests on X: "🚨 $BIAF HUGE #news! Record 2025 revenue & unit sales for CyPath® Lung: +87% revenue growth, +99% tests performed YoY. Noninvasive lung cancer detection gaining traction (VA & clinics). $4.8M cap exploding volume — breakout incoming? 🩺 #BIAF #LungCancer #Biotech #pennystocks https://t.co/oXEacF3Veu" / X 🚨 $BIAF HUGE #news! Record 2025 revenue & unit sales for CyPath® Lung: +87% revenue growth, +99% tests performed YoY. Noninvasive lung cancer detection gaining traction (VA & clinics). $4.8M cap exploding volume — breakout incoming? 🩺 #BIAF #LungCancer #Biotech #pennystocks https://t.co/oXEacF3Veu

🚨 $BIAF pre-market +50% to $1.60 on HUGE news! Record 2025 revenue & unit sales for CyPath® Lung: +87% revenue growth, +99% tests performed YoY. Noninvasive lung cancer detection gaining traction (VA & clinics). #BIAF
x.com/i/status/203...

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung bioAffinity Technologies (Nasdaq: BIAF) reported 2025 results highlighting commercialization progress for its noninvasive lung cancer test, CyPath® Lung. CyPath testing revenue rose 87% YoY and unit volume increased 99% YoY, while consolidated revenue fell 34% after discontinuing unprofitable pathology services. The company raised $16.9M, ended 2025 with $6.5M cash, and enrolled the first patient in a planned 2,000-patient longitudinal trial in March 2026.

#BIAF #BIAFW bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

www.stocktitan.net/news/BIAF/bio-affinity-t...

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic bioAffinity Technologies (Nasdaq: BIAF) initiated a 2,000-patient, large-scale longitudinal clinical study to evaluate its CyPath® Lung noninvasive flow cytometry test for detecting early-stage lung cancer in high-risk patients with 6mm–<30mm nodules.Up to 20 sites, including VA centers and major military hospitals, will enroll patients over ~18 months with follow-up to 24 months (NCT07168993). Prior data showed 92% sensitivity, 87% specificity and 88% accuracy in nodules <20mm. The investigational assay will be called FlowPath Lung during the trial.

#BIAF #BIAFW bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

www.stocktitan.net/news/BIAF/bio-affinity-t...

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients bioAffinity Technologies (Nasdaq: BIAF) presented a scientific poster at the AAAAI 2026 annual meeting on March 1, 2026, reporting that its diagnostic platform can detect antibody drug receptors in sputum for dupilumab and benralizumab.The research advances development of noninvasive tests to help match asthma and COPD patients with biologic therapies and to monitor inflammatory changes over time using the company's flow cytometry platform with automated AI analysis.

#BIAF #BIAFW bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

www.stocktitan.net/news/BIAF/bio-affinity-t...

$BIAF New case study: CyPath® Lung spares 79yo woman invasive biopsy for suspicious nodule — supports surveillance over risky procedure. Noninvasive test w/ 92% sensitivity & 87% specificity for early lung cancer detection. Tiny 4.3M float, NFS DYOR #BIAF #LungCancer #biotech ⚕️
x.com/i/status/202...

Lung cancer experts stress the importance of lung cancer screening and value of expanding screening criteria to include more at-risk individuals. See the article in Oncology Live at bit.ly/4k5NBbA and how CyPath® Lung can help at www.cypathlung.com
#lungcancerscreening #CyPathLung #BIAF #lungcancer

Cancer test lab keeps gold-standard accreditation after inspection College of American Pathologists renews bioAffinity’s lab oversight as its CyPath Lung test targets a lung cancer market projected at $10.4B by 2034.

#BIAF #BIAFW bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

www.stocktitan.net/news/BIAF/bio-affinity-t...

Most Searched, Wednesday December 10, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Dec 10th - #POM #ENVB #DNN #NXDR #IBIO #PLUG #WRBY #TMC #RDW #SBET #PSIX #PARR #ONDS #MIGI #IRBT #HUN #FLWS #QUBT #BIAF #RR - More: crystalequityresearch.com/most-searche... - #smallcap

bioAffinity Technologies (Nasdaq: BIAF) to present CyPath Lung Stage 1A cases at ACS National Lung Cancer Roundtable bioAffinity’s noninvasive CyPath Lung sputum test will be spotlighted at the ACS National Lung Cancer Roundtable, with three Stage 1A cases guiding complex nodule workups.

#BIAF #BIAFW bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

www.stocktitan.net/news/BIAF/bio-affinity-t...

#BIAF #BIAFW bioAffinity Technologies Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/BIAF/bio-affinity-t...

#BIAF #BIAFW bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

www.stocktitan.net/news/BIAF/bio-affinity-t...

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases bioAffinity Technologies (Nasdaq: BIAF) announced that IP Australia has accepted Australian patent application AU 2019253111 for its platform to assess lung health and predict multiple lung diseases. The application covers methods using flow cytometry with fluorescent probes to detect cellular and molecular signatures in sputum samples. The acceptance adds to bioAffinity’s global estate—18 awarded and 33 pending patents—and complements the company’s flagship CyPath® Lung diagnostic. The patent will be automatically issued three months after acceptance unless a third party files an opposition before issuance.

#BIAF #BIAFW bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

www.stocktitan.net/news/BIAF/bio-affinity-t...

#BIAF #黒沢ともよ

#BIAF

CHEST 2025 is underway.
#CHEST #CyPathLung #earlylungcancerdetection #lungcancer #BIAF

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer bioAffinity Technologies (Nasdaq: BIAF) received a notification of allowance from the USPTO for a patent titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.”The allowed claim covers an AI-built algorithm and automated flow cytometry system that analyzes sputum cell populations and patient age to predict early-stage lung cancer and supports the company’s commercial CyPath® Lung test. The allowance expands bioAffinity’s global estate to 18 awarded and 33 pending patents across multiple jurisdictions.

#BIAF #BIAFW bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

www.stocktitan.net/news/BIAF/bio-affinity-t...

Most Searched, Tuesday October 14, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Oct 14th - #AREC #ABAT #LAES #NVTS #WWR #UAMY #EOSE #TDUP #SERV #REKR #NRGV #NAK #LAC #DPRO #DAVE #CRML #ATXS #BIAF #MP - More: crystalequityresearch.com/most-searche... - #smallcap

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules bioAffinity Technologies (NASDAQ: BIAF, BIAFW) entered definitive agreements for a registered direct offering of 720,000 common shares at $2.50 per share, expected to close on or about October 9, 2025. Gross proceeds are expected to be approximately $1.8 million before placement agent fees and offering expenses. WallachBeth Capital is sole placement agent. The company intends to use net proceeds for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares are offered under an effective Form S-3 shelf registration (File No. 333-275608) and a prospectus supplement will be filed with the SEC.

#BIAFW #BIAF WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/BIAFW/wallach-beth-...

JUST IN: ( NASDAQ: #BIAF ) Closing Bell Spotlight: Momentum Names from Yesterday Continue to Roar

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules bioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per share in a registered direct offering...

#BIAF #BIAFW bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/BIAF/bio-affinity-t...

JUST IN: ( NASDAQ: #BIAF ) US Companies Moving the Markets, Morning edition <br>Wed, Oct 08, 2025 as of 10.00 am ET

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 bioAffinity Technologies (Nasdaq: BIAF) reported record CyPath® Lung test volumes in Q3 2025, with sales up 95% versus Q2 2025 and a 97% increase in sales for the first nine months of 2025 versus the same period in 2024. The company cited growing adoption by Veterans’ hospitals and expansion in the mid-Atlantic region.Management highlighted a 77% increase in new patients using CyPath® Lung in Q3 and improved at-home sample collection compliance. Published case studies cited earlier detection (including Stage 1A) and fewer unnecessary invasive procedures.

#BIAF #BIAFW bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

www.stocktitan.net/news/BIAF/bio-affinity-t...

11 en 12 oktober BiAF
Kunstbeurs in Antwerpen
Gratis tickets!
biaf.be/bezoeken en de code PTCP25

Openingstijden
Zaterdag 11 okt: 11.00 – 18.00 uur
Zondag 12 okt: 11.00 – 18.00 uur

#biaf #antwerpen #masterofrealism #meestersvanhetrealisme #artfair #kunstbeurs #kunst #art #painting #schilderkunst